Industry News Marrow Therapeutics BioPharma Dive
Marrow debuts with $173M for an in vivo siRNA rival to sickle cell gene therapy
- Marrow emerged from stealth with $173M across Series A and B from eleven investors, including founder Scion Life Sciences, OrbiMed and venBio.
- Lead program MAR-101 is a transferrin-receptor antibody conjugated to an siRNA, aimed at reactivating fetal hemoglobin in bone marrow cells for sickle cell disease and beta thalassemia.
- It is preclinical, with no clinical start date given; the pitch is a repeatable, titratable injection versus Casgevy and Lyfgenia.
A $173M round for a preclinical asset shows investors still want an alternative to conditioning-based cures that few patients actually receive. The open question is delivery: transferrin-receptor shuttles have moved siRNA into marrow cells only in limited settings, so hematopoietic knockdown depth and duration are what to watch. A reversible, dose-titratable drug would also be easier to price for low-income markets, but it must show fetal hemoglobin levels that approach a one-time cure.
Source: BioPharma Dive ↗ Marrow sets out to challenge genetic medicines for severe blood diseases